Genetic polymorphisms in hepatically expressed UGT1A1 and UGT1A9 contribute to the interindividual variability i-n irinotecan disposition and toxicity. We screened UGT1A1 (UGT1A1*60, g.À3140G4A, UGT1A1*28 and UGT1A1*6) and UGT1A9 (g.À118(T) 9410 and I399C4T) genes for polymorphic variants in the promoter and coding regions, and the genotypic effect of UGT1A9 I399C4T polymorphism on irinotecan disposition in Asian cancer patients was investigated. Blood samples were collected from 45 patients after administration of irinotecan as a 90 min intravenous infusion of 375 mg/m 2 once in every 3 weeks. Genotypic-phenotypic correlates showed that cancer patients heterozygous or homozygous for the I399C4T allele had approximately 2-fold lower systemic exposure to SN-38 (Po0.05) and a trend towards a higher relative extent of glucuronidation (REG) of SN-38 (P40.05). UGT1A1-1A9 diplotype analysis showed that patients harbouring the H1/H2 (TG6GT 10 T/GG6GT 9 C) diplotype had 2.4-fold lower systemic exposure to SN-38 glucuronide (SN-38G) compared with patients harbouring the H1/H5 (TG6GT 10 T/GG6GT 10 C) diplotype (P ¼ 0.025). In conclusion, this in vivo study supports the in vitro findings of Girard et al. and suggests that the UGT1A9 I399C4T variant may be an important glucuronidating allele affecting the pharmacokinetics of SN-38 and SN-38G in Asian cancer patients receiving irinotecan chemotherapy.
Introduction
Glucuronidation reactions in humans represent an important detoxification process for exogenous as well as endogenous compounds such as steroids, bile acids, environmental toxicants, hormones, carcinogens and drugs. 1 These conjugation reactions are catalysed by the multigene family of uridine di phosphate-glucuronosyltransferases (UGTs) and involves the utilization of UDPglucuronic acid as co-substrate for the transformation of hydrophobic drugs and xenobiotics into hydrophilic metabolites, thereby facilitating their elimination from the body via the renal and biliary routes. 0 -ward by 13 cassette exon 1's, each encoding one of the UGT1A first exon RNA transcripts. Each exon 1 is preceded by its own promoter region. Thirteen different proteins are encoded by the UGT1A locus, of which nine are functional (UGT1A1, UGT1A3-1A10), and four are pseudogenes(p) (UGT1A2p, UGT1A11p, UGT1A12p and UGT1A13p). Transcription of each individual first exon leads to a strategy of exon sharing, combining the first exon sequences with common exons 2-5. 3, 4 The N-terminal domain of the UGT1A proteins which are encoded by the first exon is involved in substrate-binding specificity, and the C-terminal domain encoded by the common exons 2-5 play a role in binding to UDP-glucuronic acid. 5 The UGT1A gene locus exhibits tissue-specific expression, which suggests tissuespecific glucuronidation of a broad range of substrates. Of the nine functional UGT1A proteins, five are primarily expressed in hepatic tissues (UGT1A1, UGT1A3, UGT1A4, UGT1A6 and UGT1A9) [6] [7] [8] [9] and three in extrahepatic tissues (UGT1A7, UGT1A8 and UGT1A10). 10, 11 Irinotecan (CPT-11) is a topoisomerase I inhibitor and is widely used in the treatment of metastatic colorectal cancer either in combinational therapy with 5-fluorouracil and leucovorin or as monotherapy in the second line setting. 12 Following intravenous infusion, it is hydrolysed by carboxylesterases to 7-ethyl-10-hydroxycamptothecin (SN-38), which is 100-to 1000-fold more active than irinotecan. 13 SN-38 undergoes hepatic glucuronidation by UGT1A1 to form an inactive glucuronide, SN-38G. 14, 15 Irinotecan also undergoes oxidative metabolism by the cytochrome P450 enzymes (CYP3A4 and CYP3A5) to form the major plasma metabolites 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin (NPC). 16, 17 Both APC and NPC lack cytotoxic activity, but NPC may be functionally important, as it can be hydrolysed by carboxylesterase to SN-38. 17, 18 The process of glucuronidation is extremely important in the detoxification of SN-38 and partly accounts for the observed interindividual variability in pharmacokinetics and pharmacodynamics of irinotecan. Two main toxicities due to irinotecan treatment include diarrhoea and myelosuppression, which have been associated with defective glucuronidation of the active metabolite of irinotecan, SN-38. 19, 20 Several studies have associated these toxicities with the presence of functional polymorphisms in UGT1A isoforms, such as UGT1A1 and UGT1A9 genes that impairs SN-38 glucuronidation. 21, 22 The presence of seven TA tandem repeats [g.À53(TA) 7/7 ; UGT1A1*28] instead of six [g.À53(TA) 6/6 ; UGT1A1*1)] in the promoter of UGT1A1 has been shown to be associated with low rates of SN-38 glucuronidation and the occurrence of severe irinotecan-induced toxicity. 19, 20 Additional functional polymorphisms have been discovered in the promoter (UGT1A1*60; g.-3279T4G and g.À3156G4A) and coding regions (c.211G4A, UGT1A1*6; c.1456T4G, UGT1A1*7; c.686C4A, UGT1A1*27) of the UGT1A1 gene. Some of these polymorphisms are in haplotypic linkage with each other and are associated with altered SN-38 pharmacokinetics. [23] [24] [25] Besides UGT1A1, hepatic UGT1A9 is also involved in SN-38 detoxification and displays a high affinity for SN-38. The UGT1A9 gene is also highly polymorphic and several functional variations and haplotypes associated with altered gene expression or catalytic activity have been reported. [26] [27] [28] Recently, an intonic polymorphic variant (I399C4T) in the UGT1A9 gene was found to be associated with increased glucuronidation of UGT1A1 and UGT1A9 substrates in in vitro studies using human liver microsomes. 29 The allelic frequency of this intronic variant was 0.44 in Caucasian liver samples and it was not in linkage disequilibrium with known UGT1A1 or UGT1A9 polymorphisms. The I399TT genotype was also associated with 1.7-fold higher UGT1A1 protein content and 2.5-, 1.8-and 2.0-fold higher capacity to glucuronidate SN-38, bilirubin and oestradiol, respectively, in the liver microsomal samples that harboured the reference UGT1A1 g.À53(TA) 6/6 repeats. 29 It was postulated that the I399 intronic polymorphism could be functional independently or be in linkage with as yet unidentified polymorphisms in the UGT1A gene and may represent additional molecular mechanisms modulating considerably variable irinotecan-induced toxicity in cancer patients of different ethnic backgrounds.
The objective of this study was firstly, to screen for polymorphic variants in the promoter and coding regions of UGT1A1 and UGT1A9 genes in three distinct healthy Asian population and secondly, to investigate the genotypic effect of UGT1A9 I399 polymorphism on irinotecan disposition in Asian cancer patients. Table 1 summarizes the characteristics of the healthy subjects and cancer patients enrolled in the present study. The majority of the patients were Chinese (80%) while the Malays comprised approximately 18% of the total patient population. Gastrointestinal tumours were the main tumour types for which irinotecan was indicated (77.8%), followed by non-small cell lung (11.1%), genitourinary (4.4%) and other miscellaneous tumours (6.7%) ( Table 1) .
Results

Patient demographics
Polymorphic variants in the UGT1A1 and UGT1A9 genes in Asian healthy subjects and cancer patients Table 2 depicts the genotype and allele frequencies of UGT1A1 (g.À3263T4G, g.À3140G4A, g.À53(TA) 647 and c.211G4A) and UGT1A9 (g.À118(T) 9410 and I399C4T) polymorphisms in healthy Chinese, Malay and Indian ethnic groups, the pooled Asian cancer patients and healthy liver tissues. The genotype frequencies at all loci conformed to Hardy-Weinberg equilibrium in both the healthy subjects and cancer patients. Interethnic comparisons showed the distribution of UGT1A1 g.À3140G4A and g.-53(TA) 647 polymorphisms to be approximately two-and fourfold higher in the Indian compared with the Malay (Po0.0001) and Chinese (Po0.0001) populations, respectively. The allelic frequency of UGT1A1 c.211A variant in the healthy Chinese population was three-and fivefold higher UGT1A9 intron SNP and SN-38 glucuronidation in Asians E Sandanaraj et al compared with the Malay (Po0.0006) and Indian (Po0.0001) populations, respectively. With regards to UGT1A9 I399C4T polymorphism, significant differences were only noted between the Chinese and Indian populations (Po0.0006).
Hepatic expression of UGT1A1 and UGT1A9 in relation to genotypes Large interindividual variations were observed in the hepatic expression pattern of UGT1A1 and UGT1A9 mRNA with respect to the different polymorphic variants in each of these genes. There were no significant associations between hepatic expression of UGT1A1 mRNA and UGT1A1 g.À3263T4G, g.À3140G4A and c.211G4A polymorphisms (P40.05 in each case). The median expression level of UGT1A1 mRNA was approximately 2-fold higher in liver tissues harbouring UGT1A1 (TA) 6 2 ng h ml À1 ; Po0.011). Since the UGT1A1 c.211G4A polymorphism has been found to be associated with low SN-38 glucuronidation activity and is postulated to be more important than UGT1A1 g.À53(TA) 647 polymorphism in Asians, we also analysed the impact of UGT1A9 I399C4T polymorphism on SN-38 glucuronidation in the cancer patients restricted to harbouring only the reference UGT1A1 211GG genotype. There was no significant influence of I399C4T polymorphism on SN-38 glucuronidation in cancer patients within this sub-classification. Figure 1 Plot of area under the plasma concentration-time from zero to infinity normalized by dose and body surface area (AUC 0Àinf /dose/BSA) of SN-38 (a) all the patients (n ¼ 45) and (b) the patients wild-type to UGT1A1g.À53(TA) 6/6 (n ¼ 30) in relation of UGT1A9 I399C4T genotypes in Asian cancer patients. Bars represent the median values. n, number of subjects; NS, not significant. (Figure 2 ). With regards to UGT1A1 polymorphisms, eight haplotypes were inferred based on the linkage disequilibrium data (Table 3A) . Of these, haplotypes H1 to H3 were most common and accounted for 80.8% of all haplotypes. A total of 15 UGT1A1 diplotypes were found and the most common diplotypes were H1/H2 (n ¼ 11; 24.4%), H1/H1 (n ¼ 8; 17.8%), H1/H4 (n ¼ 6; 13.3%) (Table 3B ). Haplotypes constructed based on UGT1A1-1A9 polymorphisms revealed a total of 21 haplotypes, of which H1 to H5 were the most common haplotypes with a cumulative frequency of 72.4% (Table 4A) . A total of 30 UGT1A1-1A9 diplotypes were inferred and the most common diplotypes were H1/H2 (n ¼ 5; 11.4%) and H1/H5 (n ¼ 4; 9.1%) ( Table 4B ). We also investigated the impact of UGT1A1 and UGT1A1-1A9 diplotypes on SN-38 glucuronidation activity in the cancer patients. With regards to UGT1A1 diplotypes, pairwise comparisons revealed the REG to be significantly different between H1/H1 and H1/H3 (REG, H1/H1 vs H1/H3: 6.0372.48 vs 2.0671.00; P ¼ 0.025) (Figure 3a) . With regards to UGT1A1-1A9 diplotypes, patients with diplotype H1/H2 were found to have 2.4-fold lower SN-38 glucuronidation activity compared with patients inferring the H1/H5 diplotype (C max /dose/BSA, H1/H2 vs H1/H5: 0.1670.05 vs 0.3970.13 m À5 ; P ¼ 0.025) (Figure 3b ). Pairwise analysis did not reveal a significant impact of UGT1A1 and UGT1A1-1A9 diplotypes on dose-normalized AUC 0Àinf of SN-38G in the cancer patients (P40.05).
Discussion
Both UGT1A1 and UGT1A9 are hepatically expressed and influence the extent of glucuronidation of various candidate substrates. The objective of this in vivo exploratory study was to investigate if the recently reported UGT1A9 I399C4T polymorphism influences the glucuronidation of SN-38 in Asian cancer patients. In vitro studies using human liver microsomes by Girard et al. 29 have shown that the intronic 399C4T polymorphism in the UGT1A9 gene strongly influences the hepatic glucuronidation of SN-38, the major toxic metabolite of irinotecan. Interethnic comparisons of the allelic distribution of this potentially predictive intronic polymorphism in the healthy Asian populations revealed its frequency to be 0.44, similar to those reported for the Caucasian population by Girard et al. 29 Our results also showed lack of significant difference in allele frequency of the I399C4T polymorphism between the healthy Chinese population and the cancer patient population, which comprised mainly of Chinese ethnic group, thereby suggesting lack of selection bias. 
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Genotypic-phenotypic analysis showed the I399C4T polymorphic variant was associated with a significantly lower systemic exposure to cytotoxic SN-38 and higher glucuronidating activity in patients harbouring at least a single variant allele compared to the reference population. The genotypic effect of the polymorphic variant on SN-38 exposure level and glucuronidation activity was also preserved in patients carrying only the homozygous (TA) 6/6 polymorphism in the TATA box of the UGT1A1 promoter region. The higher glucuronidation activity of the I399C4T polymorphic variant was also supported by relatively higher (2.3-fold) expression of UGT1A9 mRNA levels in liver tissues UGT1A9 intron SNP and SN-38 glucuronidation in Asians E Sandanaraj et al of subjects restricted to harbouring only the (TA) 6/6 polymorphic repeats in the TATA box region of the UGT1A1 gene. These findings suggest that the effect of UGT1A9 I399C4T polymorphism on SN-38 glucuronidation in the cancer patients restricted to only UGT1A1 (TA) 6/6 genotype might be independent of UGT1A1 (TA) 647 polymorphism. It was not possible to study the glucuronidation activity of the I399C4T variant in liver tissues homozygous for the (TA) 7/7 repeats as genotypic frequency of the latter is very low in Chinese population, which comprised the major ethnic group from whom the liver tissues were obtained. These in vivo findings were in agreement with the in vitro findings by Girard et al. 29 and suggest that the UGT1A9 I399C4T polymorphism may be another important variant in the UGT1A subfamily that may impact on the pharmacokinetics and pharmacodynamics of irinotecan and its metabolites in cancer patients of different ethnic origin. In contrast to the higher glucuronidation activity of the UGT1A9 I399C4T polymorphism when restricted to cancer patients carrying the UGT1A1(TA) 6/6 polymorphism, there was a lack of significant effect on SN-38 glucuronidation in the cancer patients restricted to homozygosity for the reference UGT1A1 c.211G4A genotype. The reason for this observation is unclear but could be due to lack of linkage between the UGT1A1 c.211G4A and UGT1A9 I399C4T polymorphisms.
UGT1A1-1A9 haplotype analysis revealed very low degree of linkage (r 2 o0.09) between the I399C4T polymorphic variant and the rest of the functional polymorphisms in the UGT1A1 gene (g.À3263T4G, g.À3140G4A, g.À53(TA) 647 and c.211G4A). There was only a weak linkage between the I399C4T variant and the UGT1A9 g.-118(T) 9410 UGT1A9 intron SNP and SN-38 glucuronidation in Asians polymorphism. These findings are in concordance with the in vitro findings of Girard et al. 29 and suggest that this intronic polymorphism is either functional independently or is in linkage with other unknown functional polymorphisms in the UGT1A subfamily. In addition to these findings, the present exploratory study also suggests that the functional impact of the I399C4T variant on SN-38 glucuronidation activity in the Asian cancer patients, at least in the Chinese and Malay cancer patients where the frequency of the intronic polymorphic variant is similar to the Caucasian population, may be similar to the latter. Further interethnic group comparisons will be needed to clarify this issue in the future.
In contrast to the impact of the I399C4T polymorphism on exposures to SN-38 and its glucuronide, a lack of phenotypic effect of the UGT1A9 g.-118(T) 9410 polymorphism was observed in the cancer patients. The -118(T) 10 allele was previously reported to be associated with a 2.6-fold increased UGT1A9 transcriptional activity as determined by in vitro luciferase assay. 30 Carlini et al. 22 showed that the -118(T) 9 allele was in complete linkage with low activity UGT1A7*2 and *3 alleles and that the -118(T) 9/9 genotype was predictive of efficacious tumour response and low toxicity in colorectal cancer patients treated with irinotecan-based regimen. A reversed clinical finding was, however, reported by Han et al. 31 in Korean cancer patients. A possible reason for the lack of a direct impact of the UGT1A9 g.-118(T) 9410 polymorphism in our cancer patients could be the absence of significant differences in hepatic mRNA expression of UGT1A9 with respect to the -118(T) 9410 polymorphism. A similar lack of association between UGT1A9 -118(T) 10 variant and UGT1A9 protein expression was previously observed by Girard et al. 27 Another probable mechanism could be due to the UGT1A9 -118(T) 9410 polymorphism being in haplotypic linkage with other high glucuronidating alleles in UGT1A1 and UGT1A9 genes, thereby obscuring a direct phenotypic effect. In the present study, the -118(T) 10 variant was completely associated with haplotype H1, which comprised of high glucuronidating activity alleles of UGT1A1 (TG6G) and UGT1A9 I399T allele (Table 4A ). This haplotypic relationship between the UGT1A9 -118(T) 10 variant and UGT1A1 high glucuronidating alleles is similar to the findings of Girard et al. 29 and further supports the hypothesis of an indirect phenotypic effect of the UGT1A9 g.-118(T) 9410 polymorphism on SN-38 glucuronidation.
Cancer patients inferred with the UGT1A1-1A9 H1/H2 diplotype (TG6GT 10 T/GG6GT 9 C; 9/10 at À118) had significantly lower glucuronidation activity compared with patients carrying the UGT1A1-1A9 H1/H5 diplotype (TG6GT 10 T/GG6GT 10 T; 10/10 at À118), (Figure 3b) . A similar trend towards low glucuronidation of SN-38 by liver microsomes was observed in Caucasian livers harbouring the diplotype I/III (9/10 at -118) compared with the liver tissues harbouring the diplotype I/I (10/10 at -118) in the study by Girard et al. 29 These findings probably suggest that subjects homozygous for the UGT1A9 -118T 10 allele may, through haplotypic linkage with high glucuronidating alleles in UGT1A1 (TG6G), have an indirect impact on SN-38 glucuronidation.
In conclusion, this clinical study supports the in vitro findings of Girard et al. 29 that the UGT1A9 I399C4T variant may be an important independent predictive allele for SN-38 glucuronidation. Furthermore, although the sample patient cohort was small in the present study, the allelic frequency of the I399T variant was found to be high and together with known functional UGT1A polymorphisms that have been described to date in the Asian population may impact on the pharmacokinetics and pharmacodynamics of SN-38 in patients receiving irinotecan chemotherapy. This exploratory study also investigated the UGT1A1-UGT1A9 haplotype and diplotype structure and their influence on SN-38 and SN-38G pharmacokinetics in the Asian population. Future studies are planned to further validate these findings in a larger patient cohort for their usefulness as a genotypic biomarker in predicting patients at high risk of irinotecan induced toxicity.
Methods
Patient eligibility
The criteria for study eligibility were as follows: patient's age between 18 and 70 years; a histologic or cytologic diagnosis of cancer; a performance status of between 0 and 2 on the Eastern Cooperative Oncology Group (ECOG) scale; no prior use of irinotecan; a life expectancy of at least 3 months; adequate haematological function (total white blood cell count X3500/ml, absolute neutrophil count X1500/ml, platelet count X100 000/ml and haemoglobin level X9 g/dl), adequate hepatic function (total bilirubin levels p2.0 mg/dl, aspartate amino transferase (AST) and alanine amino transferase (ALT) levels p2.5 times the upper limit of normal) and adequate renal function (creatinine level p1.5 g/dl or 133 mmol/l and 24-h creatinine clearance X40 ml/min). Patients were excluded if they had: Gilbert's disease, serious infectious diseases or other severe complications, such as preexisting cardiac disease, uncontrolled diabetes, bleeding or colitis; active concurrent malignancies; symptomatic brain metastases; were lactating or pregnant women, or were willing to be pregnant; or had other medical problems severe enough to prevent compliance with the protocol. None of the patients were receiving drugs, dietary supplements and/or herbal preparations known to interact with irinotecan or affect the expression and/or function of proteins relevant to irinotecan disposition. All patients gave approved informed consent before participation in the study and the protocol was approved by the institution ethics committee.
Drug administration
Irinotecan was supplied by Aventis Pharma, as 5-ml vials containing 100 mg of the drug. All patients received irinotecan at 375 mg/m 2 once in every 3 weeks as a 90-min intravenous infusion. Treatment with irinotecan were withheld in subsequent cycles if the patients experienced unacceptable toxicity, such as absolute neutrophil UGT1A9 intron SNP and SN-38 glucuronidation in Asians countp1000/ml, platelet countp100 000/ml or diarrhoea of grade 3 or 4.
Pharmacokinetic study Serial blood sampling (3 ml) for pharmacokinetic study was performed on the first day of irinotecan administration at the following time points: immediately before start of infusion (0 h); 15, 30, 45 min and 1.5 h after start of infusion; and at 5, 20 and 45 min, and 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 h after end of infusion. Owing to logistics issue and the unwillingness of patients for further blood sampling at additional prolonged time points, the last time point of blood sampling was restricted to 24 h. The blood samples were immediately centrifuged and the plasma samples were stored at À201C until analysis. Plasma concentrations of total irinotecan, SN-38 and SN-38G were analysed by a validated reversed-phase high-performance liquid chromatographic method with fluorescence detection as described in detail previously. 28 The limits of quantification for irinotecan, SN-38 and SN-38G were 3, 0.6 and 6 ng/ml, respectively. The calibration curves were linear over the concentration ranges tested, that is 3-10 000 ng/ml for irinotecan (r 2 ¼ 0.9996), 0.6-2000 ng/ml for SN-38 (r 2 ¼ 0.9996) and 6-20 000 ng/ml for SN-38G (r 2 ¼ 0.9997), in plasma. The coefficients of variation for the intraday and interday reproducibility were 7.0 and 6.4% for irinotecan, 4.4 and 3.0% for SN-38, and 2.5 and 2.0% for SN-38G, respectively.
Pharmacokinetic parameters for total irinotecan, SN-38 and SN-38G were determined by a standard nonlinear regression program, WinNonLin version 2.1 (Pharsight Inc., Mountain View, CA, USA). The following AUC ratios were calculated: the REG of SN-38 to SN-38G (AUC SNÀ38G /AUC SNÀ38 ), and the BI (AUC SNÀ38 /AUC SNÀ38G Â AUC irinotecan ). 20 
Pharmacogenetic analysis
Genomic DNA was isolated from peripheral lymphocytes according to standard methods using proteinase K digestion followed by phenol/chloroform extractions. Genotypic analysis of DNA samples involved screening of three promoter (g.À3263T4G, g.À3140G4A and g.À53(TA) 647 ) and one coding region (c.211G4A) SNPs in the UGT1A1 gene (GenBank accession number NM_000463) and a promoter SNP, g.À118T 9410 and an intronic SNP, I399C4T in the UGT1A9 gene (GenBank accession number NM_021027). The primer sequences and PCR conditions for genotyping of UGT1A1 and UGT1A9 genes are listed in Table 5 . Following PCR, the amplification products were purified using the QIAquick PCR purification kit (QIAGEN Inc., Valencia, CA, USA) and sequenced on a Beckmann Coulter CEQ 2000XL DNA Analysis System (Beckmann Coulter Inc., Fullerton, CA, USA).
Real-time PCR analysis
Genotyping and expression studies of UGT1A1 and UGT1A9 genes were performed for 40 non-cancerous (healthy) liver tissues from Chinese (n ¼ 36), Malay (n ¼ 1) and Indian (n ¼ 3) cancer patients. Primers for UGT1A1, UGT1A9 and GAPDH as endogenous control were designed using the Primer Express 1.0 program (Applied Biosystems, Foster City, CA, USA). The forward and reverse primers used for the real-time PCR (RT-PCR) analyses were: UGT1A1: forward-5 0 -TAGGCCCATCATGCCCAATA-3 0 and reverse -5 0 -ATCCCA AAGAAACCACAAT-3 0 ; UGT1A9: forward-5 0 -TGAGACCATT GATCCCAAAGAGA-3 0 and reverse -5 0 -TGCCCAACATGATC TTCATTG-3 0 ; and GAPDH: forward -5 0 -CTGAACGGGAA GCTTGTCA-3 0 and reverse -5 0 -CCAGTGGACTCCACGAC GTA-3 0 , respectively. Total RNA was extracted from the liver tissues using TRIzoL Reagent (Invitrogen Corporation, Carlsbad, CA, USA) according to the manufacturer's instructions. The quality of total RNA was examined visually by electrophoresing on a denaturing agarose gel. Reverse transcription-PCR was conducted in 20 ml of reverse transcriptase reaction mix containing 10 ml of the extracted total RNA (10 mg/ml), 1 Â Promega AMV reverse transcriptase reaction, 1 mM of dATP, 1 mM of dUTP, 1 mM of dCTP, 1 mM of dGTP, 0.5 mg of random hexamer, 40 U of ribonuclease inhibitor, and 4.5 ml of Promega AMV reverse transcriptase (Promega Corporation, WI, USA). The mixture was incubated at 251C for 10 min and subsequently at 421C for 45 min. Reverse transcriptase reaction was terminated by Abbreviations: F, forward primer; R, reverse primer.
UGT1A9 intron SNP and SN-38 glucuronidation in Asians heating at 651C for 5 min, followed by cooling at 41C for 5 min. cDNA derived from 2 ng of total RNA was used for each reaction. The 20 ml of reaction mixtures contained 10 ml of SYBR green PCR master mix (Applied Biosystems), 1 ml of cDNA template, 1 ml each of forward and reverse primers and 7 ml of RNase-free water. The reaction was performed in triplicates. The amplification of UGT1A1, UGT1A9 and endogenous controls was carried out as follows: a 10 min initial denaturation at 951C, followed by 40 cycles of 951C for 15 s and 601C for 1 min. SYBR green fluoresces when bound to DNA and the dye emission was monitored in realtime PCR using an ABI prism 7000 Sequence Detection System (Applied Biosystems). The fluorescent dye emission was a function of cycle number and was determined using the sequence detector software (Applied Biosystems), giving the threshold cycle number (C T ) at which PCR amplification reached a significant threshold. The mRNA levels of UGT1A1 and UGT1A9 in the healthy liver tissue are expressed as the amount of target normalized to the endogenous control and relative to the UGT1A1 and UGT1A9 expression level in the liver tissue harbouring the reference genotype at all loci.
Statistical analysis
The software Haploview 3.32 (Daly lab at the Broad Institute, Cambridge, MA, USA) was used for determination of UGT1A1 and UGT1A9 haplotypes as well as linkage analysis between the different polymorphisms. Diplotype analysis was performed using the HelixTree software (HelixTree s Genetics Analysis Software, Golden Helix Inc.). Pharmacokinetic parameters were reported as mean7s.d. unless otherwise indicated. The nonparametric MannWhitney U test was used to determine the relationship between genotypes/diplotypes and glucuronidation between paired groups (Po0.05 to be statistically significant) and the Kruskal-Wallis test was used to assess genotypicphenotypic correlations among the three Asian ethnic groups (Po0.016 to be statistically significant). Bonferroni correction was applied to adjust the significance level for multiple pairwise comparisons. All statistical analyses were carried out using Stata (STATA Statistical Software release 7.0, Stata Corporation, College Station, TX, USA).
